In a bid to bolster its cardiovascular pipeline, Novartis has entered into a collaboration agreement with ProFound Therapeutics aimed at advancing the discovery and development of next-generation treatments for cardiovascular diseases. Valued at up to US$775 M, the agreement grants Novartis access to ProFound’s pioneering ProFoundry Platform, an advanced technology designed to uncover novel protein targets within the human proteome. Through this alliance, Novartis seeks to unlock new therapeutic opportunities and innovation in cardiovascular disorders.